All EMA Committee for Medicinal Products for Human Use (CHMP) articles
-
NewsCHMP recommends first broad RAS-targeted therapy for metastatic pancreatic cancer
The EMA’s human medicines committee’s positive opinion is based on data showing the oral therapy reduced the risk of death by more than fifty percent compared to chemotherapy.
-
NewsCHMP meeting highlights - June 2024
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended several new medicines, including positive opinions for treatments for rare disorders.
-
NewsPositive CHMP recommendation for antibiotic combination
EMA has recommended granting a marketing authorisation for Emblaveo for treatment of infections caused by multidrug-resistant bacteria.
-
NewsEculizumab biosimilar gets positive CHMP opinion
Samsung Bioepis’ first haematology biosimilar, which references Soliris (eculizumab), has been recommended for approval by the CHMP.
-
NewsEMA’s human medicines committee (CHMP) meeting highlights - February 2023
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended eight new medicines for approval, including an enzyme replacement therapy for a rare disease.